Primary non-Hodgkin's lymphoma of the nasal cavity: Prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy

Cancer

Volumn 83, Issue 3, 1998, Pages 449-456

  Li, Ye Xiong ^a,c   Coucke, Philippe A ^b   Li, Jian Ying ^a   Gu, Da Zhong ^a   Liu, Xin Fan ^a   Zhou, Li Qiang ^a   Mirimanoff, René Olivier ^b   Yu, Zi Hao ^a   Huang, Yi Rong ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Nasal cavity; Non Hodgkin's lymphoma; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; NOSE CAVITY TUMOR; ORAL DRUG ADMINISTRATION; PARANASAL SINUS TUMOR; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NOSE NEOPLASMS; PARANASAL SINUS NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 0032147198     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980801)83:3<449::AID-CNCR13>3.0.CO;2-W     Document Type: Article

References (38)

1. Liang R, Todd D, Chan TK, Chiu E, Lie A, Kwong YL, et al. Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol 1995;13:666-70.
2. Senan S. The diagnosis and treatment of nasal lymphoma: an important cause of upper respiratory tract destruction. Clin Otolaryngol 1992;17:563-6.
3. Yamanaka N, Harabuchi Y, Kataura A. The prognostic value of Ki-67 antigen in non-Hodgkin lymphoma of Waldeyer ring and the nasal cavity. Cancer 1992;70:2342-9.
4. Campo E, Cardesa A, Alos L, Palacin A, Cobarro J, Traserra J, et al. Non-Hodgkin's lymphomas of the nasal cavity and paranasal sinuses: an immunohistochemical study. Am J Clin Pathol 1991;96:184-90.
5. Abbondanzo SL, Wenig BM. Non-Hodgkin's lymphoma of the sinonasal tract: a clinicopathologic and immunophenotypic study of 120 cases. Cancer 1995;75:1281-91.
6. Harabuchi Y, Imai S, Wakashima J, Hirao M, Kataura A, Osato T, et al. Nasal T-cell lymphoma causally associated with Epstein-Barr virus: clinicopatholigic, phenotypic, and genotypic studies. Cancer 1996;77:2137-49.
7. Mishima K, Horiuchi K. Kojya S, Takahashi H, Ohsawa M, Aozasa K. Epstein-Barr virus in patients with polymorphic reticulosis (lethal midline granuloma) from China and Japan. Cancer 1994;73:3041-6.
8. Ferry JA, Sklar J, Zukerberg LR, Harris NL. Nasal lymphoma: a clinicopathologic study with immunophenotypic and genotypic analysis. Am J Surg Pathol 1991;15:268-79.
9. Chan JKC, Ng CS, Lau WH, Lo STH. Most nasal/nasopharyngeal lymphomas are peripheral T-cell neoplasms. Am J Surg Pathol 1987;11:418-29.
10. Ye YL, Zhou MH, Lu XY, Dai YR, Wu WX. Nasopharyngeal and nasal malignant lymphoma: a clinicopathological study of 54 cases. Histopathology 1992;20:511-6.
11. Arber DA, Weiss LM, Albujar PF, Chen YY, Jaffe ES. Nasal lymphomas in Peru. High incidence of T-cell immunophenotype and Epstein-Barr virus infection. Am J Surg Pathol 1993;17:392-9.
12. Kanavaros P, Lescs MC, Briere J, Divine M, Galateau F, Joab I, et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 1993;81:2688-95.
13. Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995;76:2351-6.
14. Itami J, Itami M, Mikata A, Tamaru JI, Kaneko T, Ogata H, et al. Non-Hodgkin's lymphoma confined to the nasal cavity: its relationship to the polymorphic reticulosis and results of radiation therapy. Int j Radiat Oncol Biol Phys 1991;20:797-802.
15. Tran LM, Mark R, Fu YS, Calcaterra T, Juillard G. Primary non-Hodgkin's lymphomas of the paranasal sinuses and nasal cavity: a report of 18 cases with stage IE disease. Am J Clin Oncol 1992;15:222-5.
16. Liang R, Todd D, Chan TK, Chiu E, Choy D, Loke SL, et al. Nasal lymphoma: a retrospective analysis of 60 cases. Cancer 1990;66:2205-9.
17. Carbone PP, Kaplan HS, Mushoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
19. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part II. Analysis and examples. Br J Cancer 1977;35:1-39.
20. Greiner TC, Medeiros LJ, Jaffe ES. Non-Hodgkin's lymphoma. Cancer 1995;75:370-80.
21. Kanavaros P, Briere J, Lescs MC, Gaulard P. Epstein-Barr virus in non-Hodgkin's lymphomas of the upper respiratory tract: association with sinonasal localization and expression of NK and/or T-cell antigens by tumour cells. J Pathol 1996; 178:297-302.
22. Lee JH, Lee SS, Park JH, Kim YW, Yang MH. Prevalence of EBV RNA in sinonasal and Waldeyer's ring lymphomas. J Korean Med Sci 1994;9:281-8.
23. Weiss LM, Gaffey MJ, Chen YY, Frierson HF. Frequency of Epstein-Barr viral DNA in "Western" sinonasal and Waldeyer's ring non-Hodgkin's lymphomas. Am J Surg Pathol 1992; 16:156-62.
24. Van Gorp J, Weiping L, Jacobse K, Liu YH, Li FY, De Weger RA, et al. Epstein-Barr virus in nasal T-cell lymphomas (polymorphic reticulocvtosis/midline malignant reticulocytosis) in western China. J Pathol 1994;173:81-7.
25. Ko YH, Lee JD, Kim CM, Kirn IS, Lee MJ. Malignant lymphomas of the nasal cavity and Waldeyer's ring: clinicopathologic and immunohistochemical study. J Korean Med Sci 1992;7:314-24.
26. Emile JF, Boulland ML, Haioun C, Kanavaros P, Petrella T, Delfar-Larue MH, et al. CD5 - CD 56 + T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood 1996;87:1466-73.
27. Lu YX, Sun WY, Cao J, Shao LH. Clinicopathological and immunohistochemical features of malignant lymphoma of the Waldeyer's ring: a report of 191 cases. Chin J Oncol 1991;13:456-8.
28. Gabella G. Cardiovascular system. In: Williams PL, Bannister LH, Berry MM, Collins P, Dyscon M, Dussek JE, et al., editors. Gray's anatomy. 38th edition. New York: Churchill Livingstone, 1995:1451-626.
29. Aisenberg AC. Coherent view of non-Hodgkin's lymphoma. J Clin Oncol 1995;13:2656-75.
30. Picker LJ, Butcher EC. Physiological and molecular mechanisms of lymphocyte homing. Annu Rev Immunol 1992;10: 561-91.
31. Logsdon MD, Ha CS, Kavadi VS, Cabanilas F, Hess MA, Cox JD. Lymphoma of the nasal cavity and paranasal sinuses: improved outcome and altered prognostic factors with combined modality therapy. Cancer 1997;80:477-88.
32. Miller T, Dahlberg S, Cassady J, Spier C, Grogan T, Carlin S, et al. Three cycles of CHOP (3) plus radiotherapy (RT) is superior to eight cycles of CHOP (8) alone for localized intermediate and high grade non-Hodgkin's lymphoma (NHL): a Southwest Oncology Group Study. In:Perry MC, editor. Proceedings of the Thirty-Second Annual Meeting of the American Society of Clinical Oncology, Philadelphia, Pennsylvania, May 18-21, 1996.
33. Glick J, Kim K, Earle J, O'Connell M. An ECOG randomized phase III trial of CHOP vs. CHOP + radiotherapy (XRT) for intermediate grade early stage non-Hodgkin's lymphoma (NHL). In: Perry MC, editor. Proceedings of the Thirty-First Annual Meeting of the American Society of Clinical Oncology, Los Angeles, California, May 20-23, 1995.
34. Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Iaffe ES, et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997;89:601-9.
35. Krol AD, Hermans J, Kramer MH, Kluin PM, Kluin-Nelemans HC, Blok P, et al. Gastric lymphomas compared with lymph node lymphomas in a population-based registry differ in stage distribution and dissemination patterns but not in patients survival. Cancer 1997;79: 390-7.
36. Zucca E, Roggero E. Biology and treatment of MALT lymphoma: the state-of-the-art in 1996: a workshop at the 6th International Conference on Malignant Lymphoma. Ann Oncol 1996;7:787-92.
37. Shih LY, Liaw SJ, Kuo TT. Primary small-intestinal lymphomas in Taiwan: immunoproliferative small-intestinal disease and nonimmunoproliferative small-intestinal disease. J Clin Oncol 1994;12:1375-82.
38. Nakamura S, Akazawa K, Yao T, Tsuneyoshi M. Primary gastric lymphoma: a clinicopathologic study of 233 cases with special reference to evaluation with the MIB-1 index. Cancer 1995;76:1313-24.